Research Interests



Current Area of Research

Common people having median income cannot afford the treatment arising from using block buster anticancer drugs. The cost effective non-infringing synthetic routes are targeted for  (Sunitinib, Nintedanib and Olaparib) since they are having very high selling price with big sale but possess low number of Drug Master File (DMF) and suppliers in India. Moreover, can we find out an alternative cost effective and non-infringing synthetic routes for Centchroman for its reposition as anticancer agents? Discovered Cost Effective New Process Routes of Olaparib and Nintedanib. (Open for Licensing) 

In absence of suitable therapeutics for COVID-19, we are working to reposition few known off-patent molecules that are not available in India as possible treatment for SARS-CoV2 in collaboration with company, Ahmedabad through innovation of novel synthetic routes and filing patents on them. Research Work has been transferred to Reliance Rasayan Private Limited, Ahmedabad

Olaparib and Rucaparib analogs having mTOR inhibitory activities

HDAC inhibitors induced apoptosis and down regulated the expression and over expression of the B-cell lymphomas 2 (Bcl2). Goal is to find pyridine-based scaffolds as double acting role on Bcl2 and HDAC to induce autophagy inside the cancerous cell.  

Our lead TRSM CDRI-830 showed 15-20 fold reduction in the CFU of infected mouse lungs, which was comparable with the efficacy of ethambutol and pyrazinamide. One of the enantiomer S-TRSM (E2) has shown significantly higher MIC and MBC (in vitro as well as ex vivo) than R-TRSM (E1). The goal is to find out new asymmetric cost effective synthesis of individual enantiomers of TRSM for further bioevaluation  

To achieve cationic water-soluble amphipathic peptides derived from corannulene to counter ever emerging multi-drug resistance in bacterial infection.

Peptide based bowl derived architectures with chelation to remove Toxic substances and for Drug Delivery 

Bedaquiline inhibits  M TB ATP synthesis in mycobacteria. Q203 is also acting against MDR and XDR strains of M. tuberculosis. Our target is to synthesize hybrid molecules of bedaquiline and Q203 for potent Anti-Tubercular activity with acceptable side effects. 

Selected list of publications

Amit Kumar Jana and Gautam Panda* RSC Adv., 2013, 3, 16795–16801 DOI: 10.1039/ c3ra41778f


Extensive, ingenious harnessing of materials towards synthesis of potent bioactive molecules 

In quest for steroidomimetics, employment of chiron Amino Acids to incorporate chiral space towards difficult asymmetric steroids

 

New functionalized synthon to access chiral heterocycles and antimalarial Raphidecursinol B and anticancer Spisulosine 


Subtle changes in chemical structure of spisulosine completely switched its cytotoxic function from apoptosis to autophagy to address therapy resistance, bringing one of the hallmarks of human cancer 

Thiophene containing trisubstituted methanes [TRSMs] as identified lead against Mycobacterium tuberculosis